At a glance: IVIG — Intravenous Immunoglobulin — is a treatment made from pooled antibodies collected from thousands of blood donors and delivered through an IV. In PANS and PANDAS, it is used to help modulate the harmful immune response driving brain inflammation. It is not a first-line treatment for every child — it is generally considered when initial antibiotic and anti-inflammatory treatment has not produced adequate improvement, or when a child presents with a moderately severe to severe episode from the start.
When families first hear the word IVIG, it can feel like the conversation has suddenly escalated into territory they were not prepared for. An IV treatment made from donated blood, administered in a hospital or infusion center, discussed alongside conditions that started with a strep infection or a behavioral change — it can feel disproportionate. Why would something this intensive be part of the conversation for a child with OCD and anxiety?
Understanding what IVIG actually is, what it is doing in the body during a PANS or PANDAS episode, and when experienced providers consider it — versus when they don't — helps make sense of why it is part of the treatment landscape for this population and what role it plays within the broader treatment framework.
IVIG is not a medication in the traditional sense. It is a concentrated preparation of immunoglobulins — antibodies — collected from the plasma of thousands of blood donors, processed and purified, and delivered directly into the bloodstream through an intravenous infusion.
In healthy immune function, immunoglobulins are the proteins the immune system produces to identify and neutralize threats. When a person receives IVIG, they are receiving a large volume of normal, healthy antibodies from a broad donor pool. The reasoning behind its use in PANS and PANDAS is that flooding the immune system with normal antibodies may help modulate the harmful autoimmune response — the mistaken immune attack on brain tissue — that is driving neuropsychiatric symptoms.
The exact mechanisms by which IVIG modulates immune responses are still being studied, and multiple pathways are likely involved. What is understood is that it can dampen overactive immune signaling, shift the balance of immune activity, and in some children with PANS and PANDAS, produce meaningful and sometimes dramatic neuropsychiatric improvement.
💡 Think of it this way: imagine a crowd that has become chaotic and is moving in a harmful direction. One way to change the crowd's behavior is to flood it with calm, purposeful people moving the right way — not by removing the problematic individuals one by one, but by shifting the overall dynamics of the group. IVIG works somewhat like that — introducing a large volume of normal immune signaling that helps shift the overall immune environment away from the harmful pattern.
This distinction matters and is worth being clear about. IVIG does not treat an active infection. It does not clear strep, Mycoplasma, or any other organism that may have triggered the PANS or PANDAS episode. Its role is specifically to address the immune dysfunction — the ongoing autoimmune response — not the original infectious trigger.
This means that IVIG is generally used alongside, not instead of, treatment for any active infection. A child who still has an active strep infection being considered for IVIG will typically have that infection treated first or concurrently, because introducing an immune-modulating treatment while an active infection is present creates its own complications.
It also means that IVIG is not a cure in the sense of resolving the underlying vulnerability to PANS or PANDAS episodes. It addresses the current episode — the ongoing immune dysregulation producing the neuropsychiatric symptoms. It does not prevent future episodes triggered by future infections, though some children do show a reduction in episode frequency and severity following treatment.
IVIG is not a first step in every PANS or PANDAS treatment plan. Understanding when it tends to enter the conversation helps families know what to expect as treatment progresses — and helps them ask informed questions if their provider is or is not discussing it.
📊 Clinical situations where IVIG is generally considered in PANS/PANDAS:
IVIG is generally not the first consideration for mild presentations or first episodes with no prior treatment history. The treatment carries cost, logistical complexity, and some risk of side effects — experienced providers weigh those factors against the severity of the child's presentation and the response to earlier treatment.
IVIG is administered as an intravenous infusion, typically over the course of several hours. Depending on the dose and the protocol used by the treating provider, it may be given in one session or across two consecutive days. It is most commonly administered in a hospital infusion center or outpatient infusion clinic, though some providers arrange home infusion for appropriate candidates.
Side effects during and after infusion are possible and worth knowing about in advance. Headache is one of the most commonly reported — sometimes significant. Fatigue, flu-like symptoms, fever, and nausea are also reported. Providers typically take steps to minimize these effects, which may include pre-medication, pacing the infusion rate, and ensuring good hydration before and during treatment. Serious adverse reactions are uncommon but possible, which is why infusions are administered in a monitored setting.
The timeline for seeing a response after IVIG varies. Some children show improvement within days to a few weeks. Others have a slower trajectory. And some children require more than one course before meaningful improvement is seen. The variability in response is real, and families benefit from having realistic expectations about the range of possible timelines rather than expecting a specific outcome by a specific date.
📊 Key points about IVIG response in PANS/PANDAS:
💬 If this framework is clicking for you and you're tired of piecing things together from random posts and forums, consider joining the Spectrum Care Hub Learning Community. You'll get full access to step-by-step biomedical coursework, printable tools, and new lessons added every month. Click here for details
IVIG for PANS and PANDAS has been the subject of research for several decades, beginning with early studies by Dr. Susan Swedo and colleagues at the National Institute of Mental Health. A landmark controlled trial published in the late 1990s showed significant improvement in children with PANDAS treated with IVIG compared to placebo. Subsequent clinical experience and case series have added to the evidence base, though large randomized controlled trials remain limited.
The honest picture of the evidence is this: the research is promising and clinically meaningful, particularly for children who meet the criteria that experienced providers use to select candidates. It is not the size and quality of evidence base that exists for some conventional psychiatric medications that have been studied for decades. Families deserve to know both of those things — the genuine clinical evidence supporting its use in the right population, and the honest acknowledgment that the evidence base is still developing.
What the clinical experience consistently shows is that for children with moderate to severe PANS or PANDAS who have not responded adequately to initial treatment, IVIG represents a meaningful option — not a long shot, but a treatment with a real track record in a specific, identifiable population. That is the framework parents deserve to have when making decisions about whether to pursue it.
IVIG is expensive. The cost of the medication itself — before facility fees and provider fees — can run into thousands of dollars per course. Insurance coverage is inconsistent and often requires documentation, prior authorization, and sometimes appeals. Some families have had success with coverage when a provider submits thorough clinical documentation connecting the treatment to a specific diagnosis and a clear clinical rationale. Others have faced significant out-of-pocket costs.
This is a real and legitimate consideration that deserves to be named directly. The financial burden of IVIG on families who are already managing a complex medical situation is not trivial, and making an informed decision about whether to pursue it includes understanding what it will realistically cost and what options exist for managing that cost.
Asking your provider specifically about the insurance prior authorization process, what documentation they can provide to support coverage, and what the realistic out-of-pocket picture looks like if coverage is denied — before the infusion is scheduled — is a practical and important step.
How do I know if my child is a good candidate for IVIG? That determination requires a thorough evaluation by a provider experienced in PANS and PANDAS — including the child's symptom severity, episode history, response to prior treatment, and relevant testing results. There is no simple checklist that applies universally. What is generally true is that children with moderate to severe presentations who have not improved adequately with initial treatment are the population where IVIG is most commonly considered.
Is one course of IVIG usually enough? For some children, yes — a single course produces meaningful and durable improvement. For others, partial improvement after a first course is followed by additional courses that produce further gains. And some children require ongoing management that includes periodic IVIG as part of a longer-term strategy. What the right approach is for any individual child is something that unfolds through the treatment process rather than being determined in advance.
What should we do to prepare for an IVIG infusion? Your provider and the infusion center will give you specific preparation instructions. General principles that are commonly discussed include ensuring good hydration in the days before the infusion, planning for the child to rest following the infusion, and having a plan for managing potential headache or flu-like symptoms in the days after. Having realistic expectations about the possibility of a temporary symptom worsening in the first week following infusion — and knowing that this does not mean the treatment has failed — is also important preparation.
Can IVIG be combined with other treatments? Yes. IVIG is typically part of a broader treatment approach that includes ongoing management of any infectious triggers, anti-inflammatory support, and behavioral therapy. It is not intended as a standalone treatment that replaces those other elements. How it is combined with other interventions is a clinical decision based on the individual child's picture.
What happens if IVIG doesn't produce adequate improvement? For children who do not respond adequately to IVIG, plasmapheresis — plasma exchange — is the next immune-directed intervention that experienced providers consider. It takes a more direct approach to removing the harmful antibodies from the bloodstream rather than modulating the immune response. This is discussed in more depth in the article on plasmapheresis and when it is used.
💬 If this helped you see your child's behavior and biology in a new light, the next step is to keep building on that clarity. Our Spectrum Care Hub subscription gives you the complete course library, deeper dive modules, and ongoing support, so you don't have to navigate autism and PANS/PANDAS care alone. Click here for details
Last reviewed by Mary Margaret Burch, FNP-BC — March 2026 © 2026 Spectrum Care Hub LLC / SpectrumCareHub.com. This article is for educational purposes only. Nothing here constitutes medical advice or creates a provider-patient relationship. Always work with a qualified, licensed healthcare provider before making any medical decisions for your child.